bluebird bio, Inc., is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. Gene therapy seeks to introduce a functional copy of the defective gene into a patient’s own cells, a process called gene transfer. Through gene transfer, a functional copy of the mutated gene is delivered to the patient’s cells, thereby correcting the underlying genetic defect that causes aberrant gene expression. Initial proof-of-concept data from this study were published in Nature. The Company also plans o initiate a second Phase I/II clinical program in the United States for LentiGlobin, which the Company refers to as the HGB-204 Study, for -thalassemia major. In July 2014, Bluebird Bio Inc acquired Precision Genome Engineering, Inc.
Address
150 2nd St
CAMBRIDGE, MA 02141-2115
United States
CAMBRIDGE, MA 02141-2115
United States
Website
http://www.bluebirdbio.comKey stats and ratios
| Q4 (Dec '14) | 2014 | |
| Net profit margin | -306.04% | -191.61% |
| Operating margin | -307.17% | -238.49% |
| EBITD margin | - | -221.97% |
| Return on average assets | -17.68% | -12.47% |
| Return on average equity | -20.82% | -15.15% |
| Employees | 143 |
No comments:
Post a Comment